Literature DB >> 8627614

Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives.

D Choi1, J P Stables, H Kohn.   

Abstract

Studies have demonstrated that 2-substituted N-benzyl-2-acetamidoacetamides (2) are potent anticonvulsants. A recent investigation has led to the hypothesis that an important structural feature in 2 for maximal anticonvulsant activity is the placement of a small, substituted heteroatom moiety one atom from the C(2) site. This paper validates this hypothesis. Twelve derivatives of N-benzyl-2-acetamidopropionamide have been prepared in which six different heteroatom substituents (chloro, bromo, iodo, oxygen, nitrogen, and sulfur) were incorporated at the C(3) site. Highly potent activities were observed for the two oxygen-substituted derivatives, N-benzyl-2-acetamido-3-methoxypropionamide (18) and N-benzyl-2-acetamido-3-ethoxypropionamide (19). The ED50 values in mice following intraperitoneal (i.p.) dosing for the maximal electroshock-induced seizure test for 18 and 19 were 8.3 and 17.3 mg/kg, respectively. These values compared favorably to the ED50 value found for phenytoin (ED50 = 6.5 mg/kg). Comparable activities were observed for 18 and 19 upon oral (p.o.) administration to rats (18, ED50 = 3.9 mg/kg; 19, ED50 = 19 mg/kg; phenytoin, ED50 = 23 mg/kg). Evaluation of the individual stereoisomers for 18 demonstrated that the principal anticonvulsant activity resided in the (R)-stereoisomer. The ED50 value for (R)-18 was 4.5 mg/kg, and the ED50 for (S)-18 exceeded 100 mg/kg. This difference in activity for the two stereochemical isomers surpassed comparable values for other members within this class of compounds. The protective indices (PI = TD50/ED50) (where TD50 represents a neurotoxic dose impairing rotorod performance) for (R)-18 in mice (i.p.) and in rats (p.o.) were 6.0 and > 130, respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8627614     DOI: 10.1021/jm9508705

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  31 in total

Review 1.  Future prospects for the drug treatment of epilepsy.

Authors:  A Nicolson; J P Leach
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation.

Authors:  Yuying Wang; Joel M Brittain; Brian W Jarecki; Ki Duk Park; Sarah M Wilson; Bo Wang; Rachel Hale; Samy O Meroueh; Theodore R Cummins; Rajesh Khanna
Journal:  J Biol Chem       Date:  2010-06-09       Impact factor: 5.157

3.  The structure-activity relationship of the 3-oxy site in the anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide.

Authors:  Pierre Morieux; Christophe Salomé; Ki Duk Park; James P Stables; Harold Kohn
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

Review 4.  Diverse mechanisms of antiepileptic drugs in the development pipeline.

Authors:  Michael A Rogawski
Journal:  Epilepsy Res       Date:  2006-04-18       Impact factor: 3.045

5.  (S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5.

Authors:  Aubin Moutal; Liberty François-Moutal; Samantha Perez-Miller; Karissa Cottier; Lindsey Anne Chew; Seul Ki Yeon; Jixun Dai; Ki Duk Park; May Khanna; Rajesh Khanna
Journal:  Mol Neurobiol       Date:  2015-04-07       Impact factor: 5.590

Review 6.  Opportunities and challenges in phenotypic drug discovery: an industry perspective.

Authors:  John G Moffat; Fabien Vincent; Jonathan A Lee; Jörg Eder; Marco Prunotto
Journal:  Nat Rev Drug Discov       Date:  2017-07-07       Impact factor: 84.694

7.  H. Steve White: A Champion for Contemporary Epilepsy Research.

Authors:  Harold Kohn
Journal:  Neurochem Res       Date:  2017-01-25       Impact factor: 3.996

8.  CRMP2 Phosphorylation Drives Glioblastoma Cell Proliferation.

Authors:  Aubin Moutal; Lex Salas Villa; Seul Ki Yeon; Kyle T Householder; Ki Duk Park; Rachael W Sirianni; Rajesh Khanna
Journal:  Mol Neurobiol       Date:  2017-06-28       Impact factor: 5.590

9.  Identification of the benzyloxyphenyl pharmacophore: a structural unit that promotes sodium channel slow inactivation.

Authors:  Amber M King; Xiao-Fang Yang; Yuying Wang; Erik T Dustrude; Cindy Barbosa; Michael R Due; Andrew D Piekarz; Sarah M Wilson; Fletcher A White; Christophe Salomé; Theodore R Cummins; Rajesh Khanna; Harold Kohn
Journal:  ACS Chem Neurosci       Date:  2012-09-19       Impact factor: 4.418

10.  Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety.

Authors:  Christoph Kellinghaus
Journal:  Ther Clin Risk Manag       Date:  2009-09-24       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.